Building the bio economy through commercialisation.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Building the bio economy through commercialisation.
Released on: January 15, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Uniquest is the University of Queensland’s main commercialisation company.
  • Summary
  • Transcript
  • Participants
  • Company
Uniquest is the University of Queensland’s main commercialisation company. Mark Ashton, Senior Director of Commercial Engagement in Health, discusses UniQuest’s recent industry-university collaborations.
Uniquest is the University of Queensland’s main commercialisation company. Mark Ashton, Senior Director of Commercial Engagement in Health, discusses UniQuest’s recent industry-university collaborations.
Dr Mark Ashton joined UniQuest in 2010 and is currently the Executive Director of Intellectual Property Commercialisation. Prior to this he was the Manager of Innovation and Commercial Development for The Institute for Molecular Bioscience and Health Sciences at The University of Queensland. Before joining UniQuest Dr Ashton was the Executive Vice President, Business Development at the international biotech, Evotec AG, a company that focuses on drug discovery alliances and development partnerships with the pharmaceutical and biotech industry. Prior to leading the business development group at Evotec, Dr Ashton was President, Discovery Services at Evotec, responsible for the company’s Drug Discovery division, a division that carried out projects involving high throughput screening, parallel synthesis and medicinal chemistry to pre-clinical development. Dr Ashton has worked within the biotech and pharmaceutical industry since the early 1990’s and has both operational and commercial experience of a wide range of life science projects. He has worked with most of the major pharmaceutical companies and a number of biotech companies around the world negotiating agreements totalling in excess of $100M. Dr Ashton is the author and co-author of a number of peer reviewed scientific publications and patents including new chemical entities that have progressed to human clinical trials. He has a PhD in chemistry having worked on a medicinal chemistry focussed project sponsored by an international pharmaceutical company.
UniQuest
UniQuest is one of Australia’s leading research commercialisation companies, specialising in global technology transfer and facilitating access for all business sectors to world class university expertise, intellectual property and facilities. UniQuest's innovation portfolio includes Australia's first blockbuster vaccine Gardasil®, Australia's largest biotech IPO QRxPharma Ltd, the internationally acclaimed Triple P Positive Parenting Program, and UQ’s superconductor technology used in two-thirds of the world's MRI machines.